Lack of interaction of gabapentin with carbamazepine or valproate. Academic Article uri icon



  • Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n = 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady-state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3 1/3 days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady-state plasma CBZ/CBZ-10,11-epoxide (CBZ-E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady-state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady-state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered.

publication date

  • January 1, 1994



  • Acetates
  • Amines
  • Anticonvulsants
  • Carbamazepine
  • Cyclohexanecarboxylic Acids
  • Epilepsy
  • Valproic Acid
  • gamma-Aminobutyric Acid


Scopus Document Identifier

  • 0028212823

PubMed ID

  • 8112239

Additional Document Info


  • 35


  • 1